Drug Trial News

RSS

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

Clinical trial demonstrates safety of targeted treatment approach for deadly brain tumor in children

A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic pontine glioma (DIPG) is safe, reported Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center investigators.

3 Apr 2025

Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEF

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in JACC.

31 Mar 2025

Research shows clopidogrel as better long-term therapy than aspirin after PCI

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open blocked arteries, experienced significantly better outcomes with clopidogrel rather than aspirin as their long-term antiplatelet therapy, according to research presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

Investigational drug lorundrostat offers significant blood pressure drop compared with placebo

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.

31 Mar 2025

WARRIOR trial finds no impact of intensive therapy on heart events in women

An intensive three-drug regimen of heart medications did not significantly impact the rate of serious cardiovascular events at five years in women who experienced signs and symptoms of ischemia, or insufficient blood flow to the heart muscle, but had no blockages in their heart's arteries, according to research presented at the American College of Cardiology's Annual Scientific Session.

29 Mar 2025

Bentracimab reverses ticagrelor's antiplatelet effects during surgery and bleeding events

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major bleeding, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

29 Mar 2025

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to evaluate the use of a GLP-1 agonist to manage PAD.

29 Mar 2025

Reduced-dose apixaban proves effective in preventing blood clot recurrence in cancer patients

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral blood-thinning medication over the same extended period.

29 Mar 2025

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs).

26 Mar 2025

New trial aims to make rectal cancer more responsive to radiation

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, has opened a phase 1 trial seeking to one day transform rectal cancer from a mostly radiation-resistant disease to one that can be cured using radiation and chemotherapy.

25 Mar 2025

Besifovir dipivoxil maleate offers comparable efficacy and improved safety for hepatitis B patients

Hepatitis B is a liver infection cause by the hepatitis B virus (HBV), and long-term hepatitis B infections that last longer than six months are considered "chronic".

24 Mar 2025

£2.2 million grant supports clinical trials for liver dialysis device

Clinical trials to continue the development of a liver dialysis device to treat those with life-threatening liver disease have been funded by a grant awarded to UCL, the Royal Free Hospital and Yaqrit.

21 Mar 2025

New targeted therapy shows early success in treating pediatric high-grade gliomas

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma.

20 Mar 2025

Experimental drug shows promise in reducing risk of Alzheimer's-related dementia

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which is based at Washington University School of Medicine in St. Louis.

19 Mar 2025

Clinical trial investigates osteoporosis medication for type 1 diabetes

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States and a top research center for diabetes and other life-threatening illnesses, is leading a phase 1/2 clinical trial investigating an osteoporosis medication as a way to improve beta cell health in people with early type 1 diabetes.

19 Mar 2025

ASCOLT trial explores aspirin’s role in preventing colorectal cancer recurrence

A large-scale, international, multicentre, phase 3 clinical trial of aspirin for the secondary prevention of colorectal cancer has concluded.

17 Mar 2025

Clinical trial of vaccine candidate to prevent Lassa fever begins enrollment

A National Institutes of Health (NIH)-sponsored clinical trial of a candidate vaccine to prevent Lassa fever has begun enrolling participants at the University of Maryland School of Medicine, Baltimore.

17 Mar 2025

Adding chemotherapy to radiotherapy does not improve outcomes for cervical cancer patients

Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma indicated that the addition of chemotherapy did not improve outcomes for patients and led to increased toxicity for patients.

14 Mar 2025

1
2
3
4
...
1147
Next

Drug Trial News

Novel NK cell therapy shows strong response in lymphoma patients

Clinical trial demonstrates safety of targeted treatment approach for deadly brain tumor in children

Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEF

Research shows clopidogrel as better long-term therapy than aspirin after PCI

Investigational drug lorundrostat offers significant blood pressure drop compared with placebo

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

WARRIOR trial finds no impact of intensive therapy on heart events in women

Bentracimab reverses ticagrelor's antiplatelet effects during surgery and bleeding events

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Reduced-dose apixaban proves effective in preventing blood clot recurrence in cancer patients

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

New trial aims to make rectal cancer more responsive to radiation

Besifovir dipivoxil maleate offers comparable efficacy and improved safety for hepatitis B patients

£2.2 million grant supports clinical trials for liver dialysis device

New targeted therapy shows early success in treating pediatric high-grade gliomas

Experimental drug shows promise in reducing risk of Alzheimer's-related dementia

Clinical trial investigates osteoporosis medication for type 1 diabetes

ASCOLT trial explores aspirin’s role in preventing colorectal cancer recurrence

Clinical trial of vaccine candidate to prevent Lassa fever begins enrollment

Adding chemotherapy to radiotherapy does not improve outcomes for cervical cancer patients

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Latest News